{"id":6186,"date":"2021-12-16T14:01:45","date_gmt":"2021-12-16T14:01:45","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realheart-receives-an-eu-grant-of-2-5-million-euros-for-its-artificial-heart\/"},"modified":"2021-12-16T14:01:45","modified_gmt":"2021-12-16T14:01:45","slug":"realheart-receives-an-eu-grant-of-2-5-million-euros-for-its-artificial-heart","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realheart-receives-an-eu-grant-of-2-5-million-euros-for-its-artificial-heart\/","title":{"rendered":"Realheart receives an EU grant of 2.5 million euros for its artificial heart"},"content":{"rendered":"
Realheart has been granted 2.5 million euros in as a grant from the European Innovation Council, EIC, to support the development of the world's first artificial four-chamber heart, which is scheduled to begin clinical trials as early as 2023.<\/strong><\/div>\n

Heart failure is one of the most common causes of death in the world. An artificial heart can save many lives, but the alternative that has been available so far gives many serious side effects and is therefore rarely used. Realheart's total artificial heart is designed to mimic the way the natural heart works to reduce the risk of side effects. It can be worn permanently or while waiting for a transplant.<\/span><\/span><\/p>\n

The European Innovation Council (EIC) has been set up within the framework of the EU Horizon Europe program. The aim is to identify and support pioneering new technology and innovations all the way from early research to scaling up internationally. The EIC has now granted Realheart a grant of EUR 2.5 million, corresponding to approximately SEK 25.7 million. news alert announcing the EIC Accelerator\u2019s successful companies<\/span><\/a>.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n

– It is a very welcome contribution and that we have been awarded this grant confirms that our business plan is very well thought out.\u00a0It also opens doors to future potential investments by the EIC up to 15 million euro, which we have the possibility to negotiate for as long as we reach our milestones in this project. We have left the prototype behind and are now working fully on the clinical version of our artificial heart. This money will take us a long way on the way to the market and the many patients who are waiting for a new heart, says Ina Laura Perkins, CEO of Realheart.<\/span><\/span><\/p>\n

<\/p>\n

This disclosure contains information that Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596\/2014). The information was submitted for publication, through the agency of the contact person, on 16-12-2021 15:01 CET.<\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atriums and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. A unique concept in the medical technology world.<\/span><\/em><\/span><\/span><\/span><\/p>\n<\/div>\n